Abstract
Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.
| Original language | English |
|---|---|
| Pages (from-to) | 2676-2677 |
| Number of pages | 2 |
| Journal | Circulation Journal |
| Volume | 82 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2018 Jan 1 |
Fingerprint
Keywords
- Epoprostenol
- Giant fold gastritis
- Pulmonary arterial hypertension
- Stomach barium examination
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension. / Miura, Yohei; Kataoka, Masaharu; Chiba, Tomohiro; Inami, Takumi; Yoshino, Hideaki; Satoh, Toru.
In: Circulation Journal, Vol. 82, No. 10, 01.01.2018, p. 2676-2677.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension
AU - Miura, Yohei
AU - Kataoka, Masaharu
AU - Chiba, Tomohiro
AU - Inami, Takumi
AU - Yoshino, Hideaki
AU - Satoh, Toru
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.
AB - Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.
KW - Epoprostenol
KW - Giant fold gastritis
KW - Pulmonary arterial hypertension
KW - Stomach barium examination
UR - http://www.scopus.com/inward/record.url?scp=85054087253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054087253&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-18-0349
DO - 10.1253/circj.CJ-18-0349
M3 - Article
VL - 82
SP - 2676
EP - 2677
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 10
ER -